FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:FOXP1-PDZRN3

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: FOXP1-PDZRN3
FusionPDB ID: 31210
FusionGDB2.0 ID: 31210
HgeneTgene
Gene symbol

FOXP1

PDZRN3

Gene ID

27086

23024

Gene nameforkhead box P1PDZ domain containing ring finger 3
Synonyms12CC4|HSPC215|MFH|QRF1|hFKH1BLNX3|SEMACAP3|SEMCAP3
Cytomap

3p13

3p13

Type of geneprotein-codingprotein-coding
Descriptionforkhead box protein P1fork head-related protein like Bglutamine-rich factor 1mac-1-regulated forkheadE3 ubiquitin-protein ligase PDZRN3RING-type E3 ubiquitin transferase PDZRN3ligand of Numb protein X 3likely ortholog of mouse semaF cytoplasmic domain associated protein 3semaphorin cytoplasmic domain-associated protein 3
Modification date2020032920200313
UniProtAcc

Q9H334

Main function of 5'-partner protein: FUNCTION: Transcriptional repressor (PubMed:18347093, PubMed:26647308). Can act with CTBP1 to synergistically repress transcription but CTPBP1 is not essential (By similarity). Plays an important role in the specification and differentiation of lung epithelium. Acts cooperatively with FOXP4 to regulate lung secretory epithelial cell fate and regeneration by restricting the goblet cell lineage program; the function may involve regulation of AGR2. Essential transcriptional regulator of B-cell development. Involved in regulation of cardiac muscle cell proliferation. Involved in the columnar organization of spinal motor neurons. Promotes the formation of the lateral motor neuron column (LMC) and the preganglionic motor column (PGC) and is required for respective appropriate motor axon projections. The segment-appropriate generation of spinal chord motor columns requires cooperation with other Hox proteins. Can regulate PITX3 promoter activity; may promote midbrain identity in embryonic stem cell-derived dopamine neurons by regulating PITX3. Negatively regulates the differentiation of T follicular helper cells T(FH)s. Involved in maintenance of hair follicle stem cell quiescence; the function probably involves regulation of FGF18 (By similarity). Represses transcription of various pro-apoptotic genes and cooperates with NF-kappa B-signaling in promoting B-cell expansion by inhibition of caspase-dependent apoptosis (PubMed:25267198). Binds to CSF1R promoter elements and is involved in regulation of monocyte differentiation and macrophage functions; repression of CSF1R in monocytes seems to involve NCOR2 as corepressor (PubMed:15286807, PubMed:18799727, PubMed:18347093). Involved in endothelial cell proliferation, tube formation and migration indicative for a role in angiogenesis; the role in neovascularization seems to implicate suppression of SEMA5B (PubMed:24023716). Can negatively regulate androgen receptor signaling (PubMed:18640093). Acts as a transcriptional activator of the FBXL7 promoter; this activity is regulated by AURKA (PubMed:28218735). {ECO:0000250|UniProtKB:P58462, ECO:0000269|PubMed:15286807, ECO:0000269|PubMed:18640093, ECO:0000269|PubMed:18799727, ECO:0000269|PubMed:24023716, ECO:0000269|PubMed:25267198, ECO:0000269|PubMed:26647308, ECO:0000269|PubMed:28218735, ECO:0000305|PubMed:18347093, ECO:0000305|PubMed:24023716}.; FUNCTION: [Isoform 8]: Involved in transcriptional regulation in embryonic stem cells (ESCs). Stimulates expression of transcription factors that are required for pluripotency and decreases expression of differentiation-associated genes. Has distinct DNA-binding specifities as compared to the canonical form and preferentially binds DNA with the sequence 5'-CGATACAA-3' (or closely related sequences) (PubMed:21924763). Promotes ESC self-renewal and pluripotency (By similarity). {ECO:0000250|UniProtKB:P58462, ECO:0000269|PubMed:21924763}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000318789, ENST00000468577, 
ENST00000475937, ENST00000484350, 
ENST00000491238, ENST00000493089, 
ENST00000498215, ENST00000318779, 
ENST00000472382, 
ENST00000462146, 
ENST00000466780, ENST00000479530, 
ENST00000535920, ENST00000308537, 
ENST00000466348, ENST00000263666, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score34 X 30 X 13=132603 X 5 X 3=45
# samples 385
** MAII scorelog2(38/13260*10)=-5.124937546669
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(5/45*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: FOXP1 [Title/Abstract] AND PDZRN3 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: FOXP1 [Title/Abstract] AND PDZRN3 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)FOXP1(71026793)-PDZRN3(73453546), # samples:1
PDZRN3(73651505)-FOXP1(71102924), # samples:1
Anticipated loss of major functional domain due to fusion event.FOXP1-PDZRN3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FOXP1-PDZRN3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
FOXP1-PDZRN3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FOXP1-PDZRN3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PDZRN3-FOXP1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PDZRN3-FOXP1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
FOXP1-PDZRN3 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
FOXP1-PDZRN3 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
FOXP1-PDZRN3 seems lost the major protein functional domain in Hgene partner, which is a transcription factor due to the frame-shifted ORF.
FOXP1-PDZRN3 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
FOXP1-PDZRN3 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneFOXP1

GO:0002903

negative regulation of B cell apoptotic process

25267198

HgeneFOXP1

GO:0010629

negative regulation of gene expression

30111844

HgeneFOXP1

GO:0030316

osteoclast differentiation

18799727

HgeneFOXP1

GO:0032496

response to lipopolysaccharide

18799727

HgeneFOXP1

GO:0032680

regulation of tumor necrosis factor production

18799727

HgeneFOXP1

GO:0035926

chemokine (C-C motif) ligand 2 secretion

18799727

HgeneFOXP1

GO:0036035

osteoclast development

18799727

HgeneFOXP1

GO:0042116

macrophage activation

18799727

HgeneFOXP1

GO:0042117

monocyte activation

18799727

HgeneFOXP1

GO:0045655

regulation of monocyte differentiation

15286807

HgeneFOXP1

GO:0045892

negative regulation of transcription, DNA-templated

20950788

HgeneFOXP1

GO:0050706

regulation of interleukin-1 beta secretion

18799727

HgeneFOXP1

GO:0050727

regulation of inflammatory response

18799727

HgeneFOXP1

GO:0060766

negative regulation of androgen receptor signaling pathway

18640093

HgeneFOXP1

GO:1900424

regulation of defense response to bacterium

18799727

HgeneFOXP1

GO:1901256

regulation of macrophage colony-stimulating factor production

18799727

HgeneFOXP1

GO:2001182

regulation of interleukin-12 secretion

18799727



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:71026793/chr3:73453546)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across FOXP1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PDZRN3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000475937FOXP1chr371026793-ENST00000263666PDZRN3chr373453546-5074185943141411236
ENST00000491238FOXP1chr371026793-ENST00000263666PDZRN3chr373453546-4803158815438701238
ENST00000498215FOXP1chr371026793-ENST00000263666PDZRN3chr373453546-4966175132340331236
ENST00000468577FOXP1chr371026793-ENST00000263666PDZRN3chr373453546-46431428037101236

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000475937ENST00000263666FOXP1chr371026793-PDZRN3chr373453546-0.0074004040.9925996
ENST00000491238ENST00000263666FOXP1chr371026793-PDZRN3chr373453546-0.0055606860.99443936
ENST00000498215ENST00000263666FOXP1chr371026793-PDZRN3chr373453546-0.0065192340.9934808
ENST00000468577ENST00000263666FOXP1chr371026793-PDZRN3chr373453546-0.0056625120.9943375

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for FOXP1-PDZRN3

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
FOXP1chr371026793PDZRN3chr3734535461428475EVRPPFTYASLIRQVNGRDLSRATHD
FOXP1chr371026793PDZRN3chr3734535461588477EVRPPFTYASLIRQVNGRDLSRATHD
FOXP1chr371026793PDZRN3chr3734535461751475EVRPPFTYASLIRQVNGRDLSRATHD
FOXP1chr371026793PDZRN3chr3734535461859475EVRPPFTYASLIRQVNGRDLSRATHD

Top

Potential FusionNeoAntigen Information of FOXP1-PDZRN3 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FOXP1-PDZRN3_71026793_73453546.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FOXP1-PDZRN3chr371026793chr3734535461428HLA-B52:01YASLIRQV0.99930.9296715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C15:06YASLIRQV0.99990.8517715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C06:03YASLIRQV0.99940.9933715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C12:04YASLIRQV0.99940.9944715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-B51:07YASLIRQV0.99930.7908715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C12:12YASLIRQV0.99920.8977715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C02:06YASLIRQV0.99660.965715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:05TYASLIRQV0.44720.96615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C04:14TYASLIRQV0.24340.9324615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:19TYASLIRQV0.20480.6178615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:10TYASLIRQV0.19170.9157615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:67TYASLIRQV0.19010.9143615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:80TYASLIRQV0.19010.9143615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:46TYASLIRQV0.16780.8296615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:95TYASLIRQV0.16760.7054615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:27TYASLIRQV0.15010.9524615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:29TYASLIRQV0.14820.949615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:13TYASLIRQV0.14420.8822615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C12:16TYASLIRQV0.02960.9435615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C15:02YASLIRQV0.99990.8102715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C03:17YASLIRQV0.99980.9767715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C16:02YASLIRQV0.99940.9924715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C16:04YASLIRQV0.99910.9771715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C12:03YASLIRQV0.99790.9668715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C16:01YASLIRQV0.99770.9809715
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C06:08TYASLIRQV0.41840.9825615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C06:02TYASLIRQV0.32340.9891615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C06:17TYASLIRQV0.32340.9891615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C04:04TYASLIRQV0.30920.8938615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:17TYASLIRQV0.20580.9392615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:02TYASLIRQV0.19010.9143615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:22TYASLIRQV0.18040.7189615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:01TYASLIRQV0.17340.7015615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C07:04TYASLIRQV0.12140.9421615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C03:67TYASLIRQV0.0860.9839615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C06:06TYASLIRQV0.05420.9882615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C14:02TYASLIRQV0.02730.9615615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-C14:03TYASLIRQV0.02730.9615615
FOXP1-PDZRN3chr371026793chr3734535461428HLA-A68:02FTYASLIRQV0.99710.5788515
FOXP1-PDZRN3chr371026793chr3734535461428HLA-A69:01FTYASLIRQV0.99410.5799515

Top

Potential FusionNeoAntigen Information of FOXP1-PDZRN3 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
FOXP1-PDZRN3_71026793_73453546.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0801PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0802PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0802PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0803PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0805PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0808PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0809PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0809PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0811PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0813PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0813PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0814PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0815PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0815PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0816PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0818PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0821PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0821PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0823PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0824PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0824PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0826PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0827PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0830PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0830PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0832PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0832PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0833PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0835PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0836PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0837PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0837PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0838PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0839PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-0902RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1101PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1101PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1105PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1105PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1108PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1108PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1109PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1109PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1110PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1110PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1112PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1112PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1115PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1115PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1119PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1119PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1124PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1124PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1127PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1127PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1128PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1128PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1129PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1129PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1130PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1130RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1131PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1131PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1132PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1132PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1133PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1133PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1137PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1137PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1139PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1139PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1145PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1145PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1149PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1149PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1151PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1151PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1161PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1161PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1162PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1162PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1164PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1164PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1166PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1166PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1169PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1172PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1172PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1172RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1173PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1174PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1174PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1175PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1175PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1180PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1180PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1181PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1181PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1187PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1187PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1190PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1190PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1191PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1191PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1193PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1194PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1194PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1195PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1195PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1196PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1196PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1305PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1305PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1307PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1307PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-13100PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1312PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1313PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1313PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1314PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1314PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1321PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1321PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1326PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1326PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1326RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1330PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1346PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1347PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1347PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1349PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1349PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1350PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1350PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1355PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1355PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1356PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1356PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1360PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1360PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1362PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1362PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1382PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1382PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1385PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1386PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1402PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1403PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1403PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1403RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1413PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1422PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1422PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1425PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1425PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1427PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1427PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1427RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1430PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1440PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1440PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1440RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1441PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1453PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1453PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1463PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1463PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1463RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1467PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1467PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1467RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1469PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1477PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1477PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1477RPPFTYASLIRQVNG217
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1485PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1485PPFTYASLIRQVNGR318
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1494PFTYASLIRQVNGRD419
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1615ASLIRQVNGRDLSRA823
FOXP1-PDZRN3chr371026793chr3734535461428DRB1-1615YASLIRQVNGRDLSR722

Top

Fusion breakpoint peptide structures of FOXP1-PDZRN3

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
9757TYASLIRQVNGRDLFOXP1PDZRN3chr371026793chr3734535461428

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of FOXP1-PDZRN3

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN9757TYASLIRQVNGRDL-7.9962-8.1096
HLA-B14:023BVN9757TYASLIRQVNGRDL-5.70842-6.74372
HLA-B52:013W399757TYASLIRQVNGRDL-6.83737-6.95077
HLA-B52:013W399757TYASLIRQVNGRDL-4.4836-5.5189
HLA-A11:014UQ29757TYASLIRQVNGRDL-10.0067-10.1201
HLA-A11:014UQ29757TYASLIRQVNGRDL-9.03915-10.0745
HLA-A24:025HGA9757TYASLIRQVNGRDL-6.56204-6.67544
HLA-A24:025HGA9757TYASLIRQVNGRDL-5.42271-6.45801
HLA-B44:053DX89757TYASLIRQVNGRDL-7.85648-8.89178
HLA-B44:053DX89757TYASLIRQVNGRDL-5.3978-5.5112
HLA-A02:016TDR9757TYASLIRQVNGRDL-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of FOXP1-PDZRN3

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
FOXP1-PDZRN3chr371026793chr373453546515FTYASLIRQVACATATGCATCTTTAATTAGGCAGGTCAAC
FOXP1-PDZRN3chr371026793chr373453546615TYASLIRQVTATGCATCTTTAATTAGGCAGGTCAAC
FOXP1-PDZRN3chr371026793chr373453546715YASLIRQVGCATCTTTAATTAGGCAGGTCAAC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
FOXP1-PDZRN3chr371026793chr373453546217RPPFTYASLIRQVNGCCACCATTTACATATGCATCTTTAATTAGGCAGGTCAACGGCAGA
FOXP1-PDZRN3chr371026793chr373453546318PPFTYASLIRQVNGRCCATTTACATATGCATCTTTAATTAGGCAGGTCAACGGCAGAGAC
FOXP1-PDZRN3chr371026793chr373453546419PFTYASLIRQVNGRDTTTACATATGCATCTTTAATTAGGCAGGTCAACGGCAGAGACTTA
FOXP1-PDZRN3chr371026793chr373453546722YASLIRQVNGRDLSRGCATCTTTAATTAGGCAGGTCAACGGCAGAGACTTATCCAGAGCA
FOXP1-PDZRN3chr371026793chr373453546823ASLIRQVNGRDLSRATCTTTAATTAGGCAGGTCAACGGCAGAGACTTATCCAGAGCAACT

Top

Information of the samples that have these potential fusion neoantigens of FOXP1-PDZRN3

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADFOXP1-PDZRN3chr371026793ENST00000468577chr373453546ENST00000263666TCGA-D7-6519

Top

Potential target of CAR-T therapy development for FOXP1-PDZRN3

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to FOXP1-PDZRN3

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to FOXP1-PDZRN3

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource